See the DrugPatentWatch profile for cosentyx

There is currently no definitive scientific evidence to suggest that Cosentyx (secukinumab) directly alters the effectiveness of inactivated vaccines. However, it is important to note that patients taking Cosentyx or other immunosuppressive drugs may have a reduced immune response to vaccines [1].

Cosentyx is a human monoclonal antibody that specifically binds to interleukin-17A (IL-17A), a cytokine involved in the inflammatory response [2]. By inhibiting IL-17A, Cosentyx is used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [2].

According to DrugPatentWatch.com, Cosentyx is marketed by Novartis and was first approved by the FDA in January 2015 [3]. The lack of specific studies evaluating the impact of Cosentyx on inactivated vaccine effectiveness may be due to the relatively recent introduction of the drug to the market.

Healthcare professionals should consider the potential impact of Cosentyx on vaccine effectiveness when making treatment decisions for their patients [1]. The Centers for Disease Control and Prevention (CDC) recommends administering vaccines prior to starting immunosuppressive therapy when possible [4]. If a patient is already taking Cosentyx, the CDC advises consulting with the patient's healthcare provider to determine the best course of action [4].

In summary, while there is no direct evidence that Cosentyx alters the effectiveness of inactivated vaccines, patients taking immunosuppressive drugs like Cosentyx may have a reduced immune response to vaccines. Healthcare professionals should consider this when making treatment decisions and administering vaccines.

Sources:
[1] European Medicines Agency. Cosentyx (secukinumab): Summary of product characteristics. <https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf>
[2] National Psoriasis Foundation. Cosentyx (secukinumab). <https://www.psoriasis.org/treatments/systemics-biologics/biologics/cosentyx>
[3] DrugPatentWatch.com. Cosentyx (secukinumab). <https://www.drugpatentwatch.com/drugs/cosentyx>
[4] Centers for Disease Control and Prevention. Vaccination of persons with altered immunocompetence. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>